Articles from Sionna Therapeutics, Inc.

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination

WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Healthcare Conference in Miami, Florida on Wednesday, June 11th 2025 at 8:00 a.m. ET.

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna’s nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.

Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET.

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 45th Annual TD Cowen Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.

BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the closing of its upsized initial public offering of 12,176,467 shares of its common stock at a public offering price of $18.00 per share, which includes 1,588,234 shares issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock in the offering. All of the shares of common stock were sold by Sionna.

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the pricing of its upsized initial public offering of 10,588,233 shares of its common stock at a public offering price of $18.00 per share. In addition, Sionna has granted the underwriters a 30-day option to purchase up to 1,588,234 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. Sionna’s shares are scheduled to begin trading on the Nasdaq Global Market on February 7, 2025 under the ticker symbol "SION." The offering is expected to close on February 10, 2025, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Sionna.